BRAXF News and Press, Braxia Scientific Corp From 08/29/22

Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients Canada NewsWire TORONTO , Aug. 29, 2022 /CNW/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX...

Braxia Scientific ( OTCPK:BRAXF ) announced Wednesday it has completed the acquisition of a U.S. privately-held telemedicine firm - KetaMD - at $6.26M consideration. The end-to-end telemedicine platform provides at-home ketamine treatments for people suffering from d...

Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health Platform Providing Beneficial Ketamine Treatments in Florida with plans to expand across the U.S. Canada NewsWire TORONTO , Aug. 3, 2022 /CNW/ - Braxia Scientific Corp. ...

Braxia Scientific press release ( OTCPK:BRAXF ): FY Net Loss of C$12.1M Revenue of C$1.49M (+47.5% Y/Y). The net loss includes a non-cash, share-based compensation of C$2,422,562 (2021 - $2,874,857) and goodwill impairment of C$5,275,374 (2021- $nil) related to the acquisi...

Braxia Scientific Reports Fourth Quarter and FY 2022 Financial Results Canada NewsWire Achieved Health Canada Special Access Program approval to provide psilocybin-assisted therapy for depression in Ontario Completed more than 6,000 treatments to date; expa...

Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Industry Leader as VP R&D and Growth Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Indu...

Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neurops...

Braxia Scientific Expands Clinic Footprint in Canada Providing Greater Access to Network of Specialists Delivering Ketamine and Psilocybin Treatments for Depression and Related Mental Health Disorders Canada NewsWire TORONTO , June 15, 2022 /CNW/ - Braxia...

Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression Canada NewsWire TORONTO , June 2, 2022 /CNW Telbec/ - Braxia Scientific Corp. ...

Braxia Scientific (OTCPK:BRAXF) said on Friday that Canada had approved its application to the Special Access Program (SAP) to provide psilocybin-assisted psychotherapy for a patient with Major Depressive Disorder in Ontario. This is the company's first psilocybin-assisted therapy t...